Nivolumab and Relatlimab vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Short Title: CA224-1093

Enrollment Status: Recruiting

NCT #: NCT06561386

Specialty Area: Oncology

Condition Studied: Stage IV or Recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with stage IV or recurrent Non-small Cell Lung Cancer (NSCLC), non-squamous
No prior treatment for advanced or metastatic disease
PD-L1 tumor cell score greater or equal to 1%
Cannot be pregnant or breastfeeding
No untreated central nervous metastases, carcinomatous meningitis, or any other active cancer requiring treatment
No autoimmune disease

What's Involved

Participation in the study will include:

Intravenous (IV) infusion of either Nivolumab and Relatlimab or Pembrolizumab along with chemotherapy

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06561386

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews

Nivolumab and Relatlimab vs Pembrolizumab Plus Chemotherapy for Stage IV/​Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%